Sudden cardiac death (patient information): Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 53: Line 53:
==Treatment options==
==Treatment options==
* The main goal in [[treatment]] is to prevent [[sudden cardiac death]] ([[SCD]]. Options include the use of medications, [[implantable cardioverter defibrillators]] ([[ICD]]), and [[catheter ablation]] <ref name="pmid26940925">{{cite journal| author=Mazzanti A, Maragna R, Faragli A, Monteforte N, Bloise R, Memmi M | display-authors=etal| title=Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3. | journal=J Am Coll Cardiol | year= 2016 | volume= 67 | issue= 9 | pages= 1053-1058 | pmid=26940925 | doi=10.1016/j.jacc.2015.12.033 | pmc=4773513 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26940925  }} </ref> <ref name="pmid19330009">{{cite journal| author=Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE | display-authors=etal| title=Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. | journal=Nat Med | year= 2009 | volume= 15 | issue= 4 | pages= 380-3 | pmid=19330009 | doi=10.1038/nm.1942 | pmc=2904954 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19330009  }} </ref> <ref name="pmid1900101">{{cite journal| author=Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH | display-authors=etal| title=Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. | journal=N Engl J Med | year= 1991 | volume= 324 | issue= 12 | pages= 781-8 | pmid=1900101 | doi=10.1056/NEJM199103213241201 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1900101  }} </ref> <ref name="pmid1552108">{{cite journal| author=Greene HL, Roden DM, Katz RJ, Woosley RL, Salerno DM, Henthorn RW| title=The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. | journal=J Am Coll Cardiol | year= 1992 | volume= 19 | issue= 5 | pages= 894-8 | pmid=1552108 | doi=10.1016/0735-1097(92)90267-q | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1552108  }} </ref> <ref name="pmid21208947">{{cite journal| author=van Welsenes GH, van Rees JB, Borleffs CJ, Cannegieter SC, Bax JJ, van Erven L | display-authors=etal| title=Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. | journal=Europace | year= 2011 | volume= 13 | issue= 3 | pages= 389-94 | pmid=21208947 | doi=10.1093/europace/euq494 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21208947  }} </ref> <ref name="pmid20109864">{{cite journal| author=Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacrétaz E | display-authors=etal| title=Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. | journal=Lancet | year= 2010 | volume= 375 | issue= 9708 | pages= 31-40 | pmid=20109864 | doi=10.1016/S0140-6736(09)61755-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20109864  }} </ref> <ref name="pmid32183887">{{cite journal| author=Schleberger R, Jularic M, Salzbrunn T, Hacke C, Schwarzl JM, Hoffmann BA | display-authors=etal| title=Outcome of catheter ablation of non-reentrant ventricular arrhythmias in patients with and without structural heart disease. | journal=Eur J Med Res | year= 2020 | volume= 25 | issue= 1 | pages= 4 | pmid=32183887 | doi=10.1186/s40001-020-0400-y | pmc=7076989 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32183887  }} </ref>
* The main goal in [[treatment]] is to prevent [[sudden cardiac death]] ([[SCD]]. Options include the use of medications, [[implantable cardioverter defibrillators]] ([[ICD]]), and [[catheter ablation]] <ref name="pmid26940925">{{cite journal| author=Mazzanti A, Maragna R, Faragli A, Monteforte N, Bloise R, Memmi M | display-authors=etal| title=Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3. | journal=J Am Coll Cardiol | year= 2016 | volume= 67 | issue= 9 | pages= 1053-1058 | pmid=26940925 | doi=10.1016/j.jacc.2015.12.033 | pmc=4773513 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26940925  }} </ref> <ref name="pmid19330009">{{cite journal| author=Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE | display-authors=etal| title=Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. | journal=Nat Med | year= 2009 | volume= 15 | issue= 4 | pages= 380-3 | pmid=19330009 | doi=10.1038/nm.1942 | pmc=2904954 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19330009  }} </ref> <ref name="pmid1900101">{{cite journal| author=Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH | display-authors=etal| title=Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. | journal=N Engl J Med | year= 1991 | volume= 324 | issue= 12 | pages= 781-8 | pmid=1900101 | doi=10.1056/NEJM199103213241201 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1900101  }} </ref> <ref name="pmid1552108">{{cite journal| author=Greene HL, Roden DM, Katz RJ, Woosley RL, Salerno DM, Henthorn RW| title=The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. | journal=J Am Coll Cardiol | year= 1992 | volume= 19 | issue= 5 | pages= 894-8 | pmid=1552108 | doi=10.1016/0735-1097(92)90267-q | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1552108  }} </ref> <ref name="pmid21208947">{{cite journal| author=van Welsenes GH, van Rees JB, Borleffs CJ, Cannegieter SC, Bax JJ, van Erven L | display-authors=etal| title=Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. | journal=Europace | year= 2011 | volume= 13 | issue= 3 | pages= 389-94 | pmid=21208947 | doi=10.1093/europace/euq494 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21208947  }} </ref> <ref name="pmid20109864">{{cite journal| author=Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacrétaz E | display-authors=etal| title=Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. | journal=Lancet | year= 2010 | volume= 375 | issue= 9708 | pages= 31-40 | pmid=20109864 | doi=10.1016/S0140-6736(09)61755-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20109864  }} </ref> <ref name="pmid32183887">{{cite journal| author=Schleberger R, Jularic M, Salzbrunn T, Hacke C, Schwarzl JM, Hoffmann BA | display-authors=etal| title=Outcome of catheter ablation of non-reentrant ventricular arrhythmias in patients with and without structural heart disease. | journal=Eur J Med Res | year= 2020 | volume= 25 | issue= 1 | pages= 4 | pmid=32183887 | doi=10.1186/s40001-020-0400-y | pmc=7076989 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32183887  }} </ref>


==Prevention==
==Prevention==




==What to expect (Outlook/Prognosis)?==
==What to expect (Outlook/Prognosis)?==




Revision as of 20:56, 18 July 2023

For the WikiDoc page for this topic, click here


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Edzel Lorraine Co, D.M.D., M.D.

Overview

What are the symptoms of sudden cardiac death?

What causes sudden cardiac death?

Some medical problems that could cause sudden cardiac death include:

Who is at highest risk?

Diagnosis

When to seek urgent medical care?

Treatment options

Prevention

What to expect (Outlook/Prognosis)?

Possible complications

Sources

  1. ↑ Katritsis DG, Gersh BJ, Camm AJ (2016). "A Clinical Perspective on Sudden Cardiac Death". Arrhythm Electrophysiol Rev. 5 (3): 177–182. doi:10.15420/aer.2016:11:2. PMC 5248660. PMID 28116082.
  2. ↑ Bagnall RD, Weintraub RG, Ingles J, Duflou J, Yeates L, Lam L; et al. (2016). "A Prospective Study of Sudden Cardiac Death among Children and Young Adults". N Engl J Med. 374 (25): 2441–52. doi:10.1056/NEJMoa1510687. PMID 27332903.
  3. ↑ Basso C, Aguilera B, Banner J, Cohle S, d'Amati G, de Gouveia RH; et al. (2017). "Guidelines for autopsy investigation of sudden cardiac death: 2017 update from the Association for European Cardiovascular Pathology". Virchows Arch. 471 (6): 691–705. doi:10.1007/s00428-017-2221-0. PMC 5711979. PMID 28889247.
  4. ↑ Mazzanti A, Maragna R, Faragli A, Monteforte N, Bloise R, Memmi M; et al. (2016). "Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3". J Am Coll Cardiol. 67 (9): 1053–1058. doi:10.1016/j.jacc.2015.12.033. PMC 4773513. PMID 26940925.
  5. ↑ Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE; et al. (2009). "Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans". Nat Med. 15 (4): 380–3. doi:10.1038/nm.1942. PMC 2904954. PMID 19330009.
  6. ↑ Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH; et al. (1991). "Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial". N Engl J Med. 324 (12): 781–8. doi:10.1056/NEJM199103213241201. PMID 1900101.
  7. ↑ Greene HL, Roden DM, Katz RJ, Woosley RL, Salerno DM, Henthorn RW (1992). "The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II". J Am Coll Cardiol. 19 (5): 894–8. doi:10.1016/0735-1097(92)90267-q. PMID 1552108.
  8. ↑ van Welsenes GH, van Rees JB, Borleffs CJ, Cannegieter SC, Bax JJ, van Erven L; et al. (2011). "Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients". Europace. 13 (3): 389–94. doi:10.1093/europace/euq494. PMID 21208947.
  9. ↑ Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacrétaz E; et al. (2010). "Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial". Lancet. 375 (9708): 31–40. doi:10.1016/S0140-6736(09)61755-4. PMID 20109864.
  10. ↑ Schleberger R, Jularic M, Salzbrunn T, Hacke C, Schwarzl JM, Hoffmann BA; et al. (2020). "Outcome of catheter ablation of non-reentrant ventricular arrhythmias in patients with and without structural heart disease". Eur J Med Res. 25 (1): 4. doi:10.1186/s40001-020-0400-y. PMC 7076989 Check |pmc= value (help). PMID 32183887 Check |pmid= value (help).
Retrieved from "https://www.wikidoc.org/index.php?title=Sudden_cardiac_death_(patient_information)&oldid=1734707"